Newron Sweden AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1998-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.neuronova.com
Clinical Trials
8
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (100.0%)Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD
Phase 1
Terminated
- Conditions
- Parkinson's Disease
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 1
- Registration Number
- NCT02408562
- Locations
- 🇩🇪
Klinikum-Bremerhaven, Bremerhaven, Germany
🇸🇪Lund University Hospital, Lund, Sweden
🇸🇪Karolinska University Hospital Huddinge, Stockholm, Sweden
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
Phase 1
Terminated
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: sNN0029 infusion solution
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 11
- Registration Number
- NCT02269436
- Locations
- 🇧🇪
Philip Van Damme, Leuven, Belgium
🇳🇱Leonard van den Berg, Utrecht, Netherlands
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 15
- Registration Number
- NCT01999803
- Locations
- 🇧🇪
Philip Van Damme, Leuven, Belgium
🇳🇱Leonard van den Berg, Utrecht, Netherlands
A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 5
- Registration Number
- NCT01829867
- Locations
- 🇸🇪
Skåne University Hospital Lund, Lund, Sweden
🇸🇪Karolinska University Hospital Huddinge, Stockholm, Sweden
A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Newron Sweden AB
- Target Recruit Count
- 11
- Registration Number
- NCT01807338
- Locations
- 🇸🇪
Department of Neurology, Skåne University Hospital, Lund, Sweden
- Prev
- 1
- 2
- Next
News
No news found